Royalty Pharma plc·4

Jul 8, 7:37 PM ET

Reddoch James F. 4

4 · Royalty Pharma plc · Filed Jul 8, 2021

Insider Transaction Report

Form 4
Period: 2021-07-06
Reddoch James F.
EVP, Research & Investments
Transactions
  • Sale

    Class A Ordinary Shares

    2021-07-06$42.40/sh30,270$1,283,5601,240,530 total(indirect: By LLC)
  • Sale

    Class A Ordinary Shares

    2021-07-07$42.01/sh2,192$92,0871,238,338 total(indirect: By LLC)
  • Sale

    Class A Ordinary Shares

    2021-07-08$42.05/sh40,655$1,709,3801,197,683 total(indirect: By LLC)
Holdings
  • Class A Ordinary Shares

    (indirect: By IRA)
    25,030
Footnotes (3)
  • [F1]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.82 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.21 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Documents

2 files